KOALA trial launched to assess CAR-T for myeloma
The first patient has been dosed with PMCC-COE-KMA, an investigational CAR T-cell therapy being developed by Peter MacCallum Cancer Centre’s Centre of Excellence in Cellular Immunotherapy (CoE) and licensed by Australian biotechnology company HaemaLogiX.
The KOALA trial will evaluate the safety and efficacy of PMCC-COE-KMA in patients with multiple myeloma whose disease is no longer responding to standard therapies and who are not currently eligible for other CAR T-cell treatments.
PMCC-COE-KMA is designed to target Kappa Myeloma Antigen (KMA), a receptor found on multiple myeloma cells and absent from healthy immune cells. Researchers hope this differentiated approach may enable a more targeted anti-myeloma effect while reducing treatment-related toxicities.
As the manufacturing partner for the trial, Cell Therapies is responsible for producing clinical doses of PMCC-COE-KMA at its GMP-licensed cell therapy manufacturing facility in Melbourne. The company’s specialised manufacturing facility is co-located with Peter Mac, providing a streamlined pathway from research and development through to clinical delivery.
Cell Therapies CEO Dr Bev Menner said: “The successful treatment of the first patient in the KOALA trial is a significant achievement for everyone involved and demonstrates the power of bringing together world-class research, clinical expertise and advanced manufacturing capabilities.”
The Centre of Excellence in Cellular Immunotherapy and HaemaLogiX collaborated to advance PMCC-COE-KMA from early-stage development through to approval by the Therapeutic Goods Administration (TGA) to proceed into clinical testing.
Dr Rosanne Dunn, Chief Scientific Officer at HaemaLogiX, said: “We are delighted with the encouraging results from the first safely treated patient, and very pleased to be moving forward to dosing the second patient at a higher dose of KMCAR T-cell therapy. Multiple myeloma is the world’s second-most common blood cancer, and there is a significant need for therapies that do not cause immunodeficiency which may result in life threatening infections.”
